#USA #Aliso Viejo #Terumo Neuro #WEB Device #Aneurysm Treatment

Terumo Neuro Celebrates 15 Years of Innovation

Terumo Neuro, a pioneering force in neurovascular care and a subsidiary of Terumo Corporation, commemorates the 15th anniversary of its groundbreaking WEB™ Aneurysm Embolization System. Since its market debut in 2010, the WEB device has emerged as a revolutionary tool in treating wide-neck bifurcation aneurysms, shifting the treatment paradigm significantly.

A Milestone in Patient Care

The WEB device has undergone extensive clinical validation, supported by a multitude of studies and publications. More than 25,000 WEB devices have been implanted across the globe, demonstrating its effectiveness and safety. This system was notably the first intrasaccular flow disruptor, transforming the way clinicians approach aneurysm treatment by allowing for simpler and less invasive procedures compared to traditional methods that often require complex stenting and coiling.

Carsten Schroeder, the CEO of Terumo Neuro, shared his thoughts on this significant milestone, stating, "The WEB device has established a new benchmark in aneurysm treatment and has been critical in our mission to inspire substantial change in neurovascular care. As we celebrate this achievement, we remain dedicated to innovating with leading physicians to enhance patient outcomes and simplify treatment protocols."

Proven Clinical Data & Safety

The clinical efficacy of the WEB device is underscored by its robust clinical data emerging from seven global Good Clinical Practice trials, documenting over 1,464 patient-years without a single rebleed in treated aneurysms. The five-year follow-up studies have further confirmed its long-term safety, with zero device-related morbidity or mortality reported.

The WEB device stands out for its simplicity: it functions as a single-device solution, contrary to the more cumbersome approaches that necessitate extensive dual antiplatelet therapy. The introduction of the WEB 17 system, a refined version aimed at treating smaller aneurysms, highlights the continued evolution of this technology, enhancing precision and expanding treatment options for physicians.

Redefining Neurovascular Care

As part of Terumo Neuro's commitment to advancing neurovascular technology, the success of the WEB device exemplifies its dedication to creating innovative solutions that revolutionize patient care. Developed in collaboration with leading specialists, the WEB device is securing its place as the tool of choice for healthcare providers seeking effective and straightforward solutions for managing wide-neck bifurcation aneurysms.

Terumo Neuro, originally founded as MicroVention in 1997, has grown into a leading player in the field, leveraging its research and development capabilities to offer over thirty distinct products designed for treating cerebral aneurysms, ischemic stroke, carotid artery malformations, and more. Now headquartered in California, the company serves healthcare professionals in over seventy countries, committed to fostering advancements that deliver significant benefits to patients and healthcare systems alike.

In conclusion, the 15-year journey of the WEB device represents more than just a technological advancement. It reflects Terumo Neuro's relentless pursuit of excellence in patient outcomes, promising a brighter future for those affected by neurovascular conditions. As the company looks toward the next decade and beyond, it pledges to continue its role as a front-runner in transformative neurovascular treatments.

For further information, visit Terumo Neuro's official website.